Anti-hyperglycaemic and anti-obesity effects of Capparis spinosa and Chamaemelum nobile aqueous extracts in HFD mice

American Journal of Pharmacology and Toxicology

Volumn 2, Issue 3, 2007, Pages 106-110

  Lemhadri, A ^a   Eddouks, Mohamed ^a   Sulpice, Thierry ^c   Burcelin, Remy ^b  

^a MOULAY ISMAIL UNIVERSITY   (Morocco)

^b CHU RANGUEIL   (France)

^c Physiogenex   (France)

Author keywords

Body weight; High fat diet; Mice; Obesity; Oral administration

Indexed keywords

ANTIOBESITY AGENT; CAPPARIS SPINOSA EXTRACT; CHAMAEMELUM NOBILE EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CAPPARIS; CAPPARIS SPINOSA; CHAMAEMELUM; CHAMAEMELUM NOBILE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; EXPERIMENTAL MOUSE; HYPERGLYCEMIA; LIPID DIET; MALE; MOROCCO; MOUSE; NONHUMAN; OBESITY; POSTPRANDIAL STATE; TREATMENT DURATION; WEIGHT REDUCTION;

CAPPARIS SPINOSA; CHAMAEMELUM NOBILE; MUS;

EID: 38749084531     PISSN: 15574962     EISSN: 15574970     Source Type: Journal    
DOI: 10.3844/ajptsp.2007.106.110     Document Type: Article

References (24)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus., 2002. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 25(supp.1): S5-S15.
2. Germano, M.P., R. De Pasquale, V. D'Angelo, S. Catania, V. Silvari and C. Costa, 2002. Evalution of extracts and isolated fraction from Capparis spinosa L. buds as antioxidant source. Journal of Agricultural and Food Chemistry, 50: 1168-1171.
3. Ali-Shtayeh, M.S and S.I. Abu-Ghdeib, 1999. Antifungal activity of plant extracts against dermatophytes. Mycoses, 42(11-12): 665-672.
4. Gadgoli, C., and S.H. Mishra, 1999. Antihepatotoxic activity of p-methoxy benzoic acid from Capparis spinosa. Journal of Ethnopharmacology, 66: 187-192.
5. Al-Said, M.S., E.A. Abdelsattar, S.I. Khalifa, and F.S El-Feraly, 1988. Isolation and identification of an anti-inflammatory principle from Capparis spinosa. Pharmazie, 43(9): 640-641.
6. Rossi, T., M. Melegari, A. Bianchi, A. Albasini and G. Vampa, 1988. Sedative, anti-inflammatory and anti-diuretic effects induced in rats by essential oils of varieties of Anthemis nobilis: a comparative study. Pharmaceutical Research Communications, 20 (Suppl. 5): 71-74.
7. Yaniv, Z., A. Dafhi, J. Friedman and D. Palevitch, 1987. Plants used for the treatment of diabetes in Israel. Journal of Ethnopharmacology, 2: 145-151.
8. Ziyyat, A., H. Legssyer, A. Mekhfi, M. Dassouli, M. Serhrouchni and W. Benjelloun, 1997. Phytotherapy of hypertension and diabetes in Oriental Morocco. Journal of Ethnopharmacology, 58: 45-54.
9. Jouad, H., M. Haloui, H. Rhiouani, J. El Hilaly and M. Eddouks, 2001. Ethnobotanical survey of medicinal plants used for the treatment of diabetes, cardiac and renal diseases in the North centre region of Morocco (Fez-Boulemane). Journal of Ethnopharmacology, 77(2-3): 175-182.
10. Eddouks, M., M. Maghrani, A. Lemhadri, M.L. Ouahidi and H. Jouad, 2002. Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco (Tafilalet). Journal of Ethnopharmacology, 82(2-3): 97-103.
11. Eddouks, M., A. Lemhadri and J.B. Michel, 2004. Caraway and caper: potential antihyperglycaemic plants in diabetic rats. Journal of Ethnopharmacology, 94(1): 143-148.
12. Eddouks, M., A. Lemhadri, N.A. Zeggwagh and J.B. Michel, 2005. Potent hypoglycaemic activity of the aqueous extract of Chamaemelum nobile in normal and streptozotocin-induced diabetic rats. Diabetes Research and Clinical Practice, 67(3): 189-195.
13. Zhang, Y., R. Proenca, M. Maffel, M. Barone, L. Leopold and J.M. Friedman, 1994. Positional cloning of the mouse obese gene and its human homologue. Nature, 372: 425-432.
14. Surwit, R.S., C.M. Kuhun, C. Cochrane, J.A. McCubbin and M.N. Feinglos, 1988. Diet-induced type II diabetes in C57BL/6J mice. Diabetes, 37: 1163-1167.
15. Kim, J.K., J.K. Wi and J.H. Youn, 1996. Metabolic impairment precedes insulin resistance in skeletal muscle during high-fat feeding in rats. Diabetes, (5): 651-658.
16. Bavenholm, P.N., J. Pigon, C.G. Ostenson and S. Efendic, 2001. Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes, 50: 1449-1454.
17. Kruszynska, Y.T and J.M. Olefsky, 1996. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. Journal of Investigative Medicine, 44: 413-428.
18. Friedman, J.E., G.L. Dohm, N. Leggett-Frazier, C.W. Elton, E.B. Tapscott, W.P. Poriesand J.F Caro, 1992. Restoration in insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. Journal of Clinical Investigation, 89: 701-705.
19. Attele, A.S., Y.P. Zhou, J.T. Xie, J.A. Wu, L. Zhang, L. Dey, W. Pugh, P.A. Rue, K.S. Plonsky and C.S. Yuan, 2002. Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component. Diabetes, 51: 1851-1858.
20. Yun, S.N., S.J. Moon, S.K. Ko, B.O. Im, and S.H. Chung, 2004. Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice. Archives of Pharmacological Research, 27(7): 790-796.
21. Cha, Y.S., S.J. Rheeand Y.R. Heo, 2004. Acanthopanax senticosus extract prepared from cultured cells decreases adiposity and obesity indices in C57BL/6J mice fed a high fat diet. Journal of Medical Foods, 7(4): 422-429.
22. Han, L.K., M. Sumiyoshi, J. Zhang, M.X. Liu, X.F. Zhang, Y.N. Zheng, H. Okuda and Y. Kimura, 2003. Anti-obesity action of Salix matsudana leaves (Part 1). Anti-obesity action by polyphenols of Salix matsudana in high fat-diet treated rodent animals. Phytotherapy Research, 17(10): 1188-1194.
23. Seely, B.L and J.M. Olefsky, 1993. Potential cellular and genetic mechanisms for insulin resistance in common disorders of obesity and diabetes. In Insulin Resistance and Its Clinical Disorders. Moller D, Ed. Chichester, U.K., Wiley, p.187-252.
24. DeFronzo, R.A and E. Ferrannini, 1991. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 14: 173-194.